Split History
MTEM split history picture
Molecular Templates (MTEM) has 1 split in our MTEM split history database. The split for MTEM took place on August 02, 2017. This was a 1 for 11 reverse split, meaning for each 11 shares of MTEM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 90.9090909090909 share position following the split.

When a company such as Molecular Templates conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MTEM split history from start to finish, an original position size of 1000 shares would have turned into 90.9090909090909 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Molecular Templates shares, starting with a $10,000 purchase of MTEM, presented on a split-history-adjusted basis factoring in the complete MTEM split history. MTEM split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/02/2012
End date: 09/30/2022
Start price/share: $72.05
End price/share: $0.75
Dividends collected/share: $0.00
Total return: -98.96%
Average Annual Total Return: -36.65%
Starting investment: $10,000.00
Ending investment: $104.10
Years: 10.00
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for cancer and other serious diseases. Co. utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). Co. is developing ETBs for various targets, including PD-L1, HER2, and CD38. PD-L1 is central to immune checkpoint pathways and is a validated target expressed in a variety of solid tumor cancers. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. CD38 has been validated as a clinical target in the treatment of multiple myeloma. According to our MTEM split history records, Molecular Templates has had 1 split.
Date Ratio
08/02/20171 for 11
MTEM is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MYG Split History
MYGN Split History
MYL Split History
MYO Split History
NAVB Split History
NBS Split History
NBY Split History
NEOG Split History
NERV Split History
NNVC Split History

Also explore: MTEM shares outstanding history

Email EnvelopeFree MTEM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

American Virtual Cloud Technologies, Inc. (AVCT)
Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MTEM Insider Buying

MTEM Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.